Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06864507

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.

This is a randomized, double-blind, placebo-controlled phase 1/2 clinical study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of HS-10561 capsule in healthy Chinese adults and patients with chronic spontaneous urticaria.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Conditions

Chronic Spontaneous Urticaria Chronic Disease Chronic Urticaria Disease Attributes Hypersensitivity Hypersensitivity, Immediate Immune System Diseases Pathologic Processes Pathological Conditions, Signs and Symptoms Skin Diseases Skin Diseases, Vascular Skin and Connective Tissue Diseases Urticaria

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Shanghai Hospital of Skin Disease

Shanghai, Shanghai Municipality, 201203, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Written informed consent must be obtained before any assessment is performed.(SD)
  • Healthy adults aged 18-45 years (inclusive) at the time of signing the informed consent form;(SD)
  • Male participants weighing ≥ 50 kg and female participants weighing ≥ 40 kg; body mass index (weight/square of height (kg/m2)) within the range of 18-30 kg/m2 (inclusive);(SD)
  • Female participants and male participants (including their female partners) agree to use highly effective methods of contraception from the date of signing the informed consent form until 30 days after the last dose;(SD)
  • Without history of severe respiratory, gastrointestinal (such as inflammatory bowel disease, Crohn's disease, chronic diarrhea, etc.), neurological, circulatory, urinary, endocrine, musculoskeletal, immune system disorders, or a history of tumors prior to screening.(SD)
  • Written informed consent must be obtained before any assessment is performed.(MD and Phase 2)
  • Healthy adults aged 18-65 years (inclusive) at the time of signing the informed consent form;(MD and Phase 2)
  • Have been diagnosed with chronic spontaneous urticaria for ≥6 months at the time of screening;(MD and Phase 2)
  • Female participants and male participants (including their female partners) agree to use highly effective methods of contraception from the date of signing the informed consent form until 30 days after the last dose.(MD and Phase 2)

Exclusion criteria

  • Have clinically significant abnormalities in vital signs, physical examination, laboratory tests, chest X-ray/CT, or abdominal ultrasound during the screening period, which, as assessed by the investigator, may increase the participants' risk or affect the scientific validity of the study;(SD)
  • Females with a positive blood pregnancy test, breastfeeding females, or participants planning to become pregnant during the study period;(SD)
  • Any physiological or psychological condition or disease, as determined by the investigator, that could increase the risk, affect the participants' compliance, or impact the participants' ability to complete the study.(SD)
  • Chronic urticaria with a clear primary or sole trigger (chronic inducible urticaria);(MD and Phase 2)
  • Clearly defined predominant or sole trigger of their chronic urticaria (chronic inducible urticaria);(MD and Phase 2)
  • Other diseases with symptoms of urticaria or angioedema;(MD and Phase 2)
  • Other skin disease associated with chronic itching that might influence in the investigators opinion the study evaluations and results;(MD and Phase 2)
  • Pregnant or nursing (lactating) women.(MD and Phase 2)

Treatment and study plan

HS-10561

Drug

Single and multiple doses of HS-10561 orally

Placebo

Drug

Placebo

Primary outcomes

  1. Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation.(Phase 1)

    Time frame: SD：up to 7 days，MD：up to 35 days

    Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation.

  2. Change from baseline in Weekly Urticaria Activity Score (UAS7) at Week 4 (Phase 2)

    Time frame: Week 4

    The Weekly Urticaria Activity Score (UAS7) is a simple scoring system to evaluate urticaria signs and symptoms. It is based on scoring wheals (hive severity score) and itch (itch severity score) separately on a scale of 0 (no signs/symptoms) to 3 (intense signs/symptoms) over 7 days. The final score is calculated by adding together the daily scores, which can range from 0 to 6, for 7 days. This results in a maximum total score of 42 (highest urticaria severity), and a minimum possible score of 0.

Secondary outcomes

  1. Cmax

    Time frame: Day 1 up to Day 4 (SD), Day 1 up to Day 35 (MD)

    Maximum plasma concentration

  2. Tmax

    Time frame: Day 1 up to Day 4 (SD), Day 1 up to Day 35 (MD)

    Time to reach Cmax

  3. AUC

    Time frame: Day 1 up to Day 4 (SD), Day 1 up to Day 35 (MD)

    Area under the plasma concentration-time curve

  4. t½

    Time frame: Day 1 up to Day 4 (SD), Day 1 up to Day 35 (MD)

    Terminal half-life

  5. CL/F

    Time frame: Day 1 up to Day 4 (SD), Day 1 up to Day 35 (MD)

    Apparent clearance

  6. Vd/F

    Time frame: Day 1 up to Day 4 (SD), Day 1 up to Day 35 (MD)

    Apparent volume of distribution

  7. Rac

    Time frame: Day 1 up to Day 4 (SD), Day 1 up to Day 35 (MD)

    Accumulation ratio

  8. Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation.(Phase 2)

    Time frame: up to 16 weeks

    Incidence, severity and association with the study drug of adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation；Clinically significant changes in physical examination and anamnesis, vital signs, ECG, safety laboratory will be reported under (S)AEs.

  9. Change from baseline in Weekly Itch Severity Score (ISS7) at Week 12(Phase 2)

    Time frame: Week 12

    The severity of the itch was recorded by the participant daily in their electronic Diary, on a scale of 0 (none) to 3 (severe). A weekly score (ISS7) was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 - 21 (highest itch severity).

  10. Change from baseline in Weekly Hives Severity Score (HSS7) at Week 12(Phase 2)

    Time frame: Week 12

    The hives (wheals) severity score, defined by number of hives, was recorded by the participant daily in their electronic Diary, on a scale of 0 (none) to 3 (> 12 hives/12 hours). A weekly score (HSS7) was derived by adding up the average daily scores of the 7 days preceding the visit. The possible range of the weekly score was therefore 0 - 21 (highest hives activity).

Sponsors and collaborators

Lead sponsor

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Industry

Registry information

Official study title

A Randomized, Double-blind, Placebo-controlled Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of HS-10561 Capsule in Healthy Chinese Adults and Patients With Chronic Spontaneous Urticaria.

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Mar 7, 2025
Registry last updated
Mar 7, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.